title: Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy.
abstract: Tamoxifen, a synthetic antiestrogen, has been shown to be effective in reducing mortality from breast cancer and the occurrence of contralateral breast cancer. Tamoxifen is now being studied as a preventive of breast cancer among healthy women considered to be at high risk; preventive trials are now under way both in the USA and in Europe. We undertook a case-control study in Lyon and Dijon, France, to assess the effect of tamoxifen and other treatments for breast cancer on subsequent endometrial cancer. Through the use of clinicians' surveys in Lyon and a population-based cancer registry in Dijon, we identified 43 cases of endometrial cancer diagnosed at least 1 year after the diagnosis of breast cancer. We matched 177 controls to the cases for age, region, year of diagnosis of breast cancer, and survival from breast cancer. Tamoxifen had been used in 67% of cases and 60% of controls [odds ratio (OR) = 1.4; 95% confidence interval (CI) = 0.60-3.5]. Relative risk of endometrial cancer increased with duration of tamoxifen use: less than 2 years, 1.5; 95% CI = 0.44-4.9; 2-5 years, 1.5; 95% CI = 0.42-5.6; more than 5 years, 3.5; 95% CI = 0.94-12.7. Radiotherapeutic castration increased the risk for endometrial cancer more than tamoxifen (OR = 7.7; 95% CI = 1.8-32.8).
authors.affiliation: Program of Epidemiology for Cancer Prevention, International Agency for Research on Cancer, Lyon, France.
authors.forename: A J
authors.initials: AJ
authors.lastname: Sasco
authors.forename: G
authors.initials: G
authors.lastname: Chaplain
authors.forename: E
authors.initials: E
authors.lastname: Amoros
authors.forename: S
authors.initials: S
authors.lastname: Saez
mesh_terms: D000230:Adenocarcinoma / Q000139:chemically induced / Q000453:epidemiology; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D016022:Case-Control Studies; D016001:Confidence Intervals; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D016555:Matched-Pair Analysis; D008875:Middle Aged; D009381:Neoplasms, Radiation-Induced / Q000453:epidemiology / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000453:epidemiology; D016017:Odds Ratio; D010052:Ovariectomy / Q000009:adverse effects* / Q000379:methods; D013629:Tamoxifen / Q000009:adverse effects*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen